{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:22:17Z","timestamp":1793190137841,"version":"4.5.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>In der Folge neuer Empfehlungen der Weltgesundheitsorganisation (WHO) zur Therapie der Tuberkulose (TB) im Jahr 2025 hat sich die Tuberkulose-Leitliniengruppe f\u00fcr Deutschland, \u00d6sterreich und die Schweiz entschlossen, die Leitlinien f\u00fcr die Therapie der medikamentenresistenten Tuberkulose (engl. drug-resistant tuberculosis; DR-TB) zu aktualisieren.<\/jats:p>\n                  <jats:p>DR-TB umfasst resistente Formen von Mycobacterium tuberculosis, darunter Isoniazid-Monoresistenz, multiresistente\/Rifampicin-resistente TB (MDR\/RR-TB), pr\u00e4extensiv resistente TB (pr\u00e4-XDR-TB) und extensiv resistente TB (XDR-TB). F\u00fcr MDR\/RR-TB und pr\u00e4-XDR-TB ohne zus\u00e4tzliche Resistenz gegen Bedaquilin oder Linezolid werden bevorzugt zwei 6-monatige, rein orale Kurzzeitregime empfohlen (BPaLM* oder BDLLfx* bei MDR\/RR-TB und BPaL* oder BDLC* bei pr\u00e4-XDR-TB [*B\u200a=\u200aBedaquilin, C\u200a=\u200aClofazimin, D\u200a=\u200aDelamanid, L\u200a=\u200aLinezolid, Lfx\u200a=\u200aLevofloxacin, M\u200a=\u200aMoxifloxacin, Pa\u200a=\u200aPretomanid]). Bei schwerer oder ausgedehnter Erkrankung sowie Immunsuppression sollte die Therapie auf z.\u200aB. 9 Monate verl\u00e4ngert oder als individualisiertes 18-Monats-Regime durchgef\u00fchrt werden. F\u00fcr XDR-TB sowie Unvertr\u00e4glichkeiten gegen\u00fcber Bedaquilin oder Linezolid gelten individualisierte Kombinationstherapien mit mindestens 4 wirksamen Substanzen \u00fcber mindestens 18 Monate. Neben pharmakologischen Aspekten betont diese Aktualisierung die Bedeutung qualit\u00e4tsgesicherter Diagnostik, gesicherter Medikamentenversorgung und sozialmedizinischer Begleitung zur Vermeidung von Therapieabbr\u00fcchen. Aufgrund der geringen Fallzahlen wird eine Behandlung in spezialisierten Zentren oder in Kooperation mit diesen empfohlen. Ziel ist eine wirksame, vertr\u00e4gliche und an die Resistenzlage angepasste Behandlung, um den Therapieerfolg zu sichern und eine weitere Resistenzentwicklung zu verhindern.<\/jats:p>","DOI":"10.1055\/a-2731-0729","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:40:17Z","timestamp":1762213217000},"page":"160-167","source":"Crossref","is-referenced-by-count":2,"title":["Update: Therapie der medikamentenresistenten Tuberkulose (DR-TB) in Deutschland, \u00d6sterreich und der Schweiz"],"prefix":"10.1055","volume":"80","author":[{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[{"name":"Klinische Infektiologie, Forschungszentrum Borstel, Leibniz Lungenzentrum, Borstel, Deutschland"},{"name":"Deutsches Zentrum f\u00fcr Infektionsforschung (DZIF), TTU-TB, ClinTB, Standort Hamburg-L\u00fcbeck-Borstel-Riems, Deutschland"},{"name":"Respiratory Medicine & International Health, Universit\u00e4t zu L\u00fcbeck, L\u00fcbeck, Deutschland"},{"name":"Baylor College of Medicine, Houston TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Schaberg","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Otto-Knapp","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"f\u00fcr die Autorinnen und Autoren der Tuberkulose-Leitliniengruppe f\u00fcr Deutschland, \u00d6sterreich und die Schweiz:","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref1","first-page":"727","article-title":"[Tuberculosis in adulthood \u2013 The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients]","volume":"76","author":"T Schaberg","year":"2022","journal-title":"Pneumologie"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"K Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2500173","DOI":"10.2807\/1560-7917.ES.2025.30.11.2500173","article-title":"Shifting tuberculosis dynamics in the EU\/EEA: geographical and drug resistance trends among people of foreign origin, 2019 to 2023","volume":"30","author":"A Vasiliu","year":"2025","journal-title":"Euro Surveill"},{"key":"ref5","first-page":"3","article-title":"Welttuberkulosetag 2025 \u2013 Yes! We Can End TB: Commit, Invest, Deliver","volume":"12","author":"I Friesen","year":"2025","journal-title":"Epid Bull"},{"key":"ref6","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid2103.141343","article-title":"Multidrug-resistant tuberculosis in Europe, 2010-2011","volume":"21","author":"G Gunther","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2401612","DOI":"10.1183\/13993003.01612-2024","article-title":"Tuberculosis in adult migrants in Europe: a TBnet consensus statement","volume":"65","author":"H Kunst","year":"2025","journal-title":"Eur Respir J"},{"key":"ref9","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment and care","author":"World Health Organization","year":"2025"},{"key":"ref10","volume-title":"WHO consolidated operational handbook on tuberculosis. Module 4: treatment and care","author":"World Health Organization","year":"2025"},{"key":"ref11","first-page":"35","article-title":"[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland \u2013 Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]","volume":"78","author":"R Otto-Knapp","year":"2024","journal-title":"Pneumologie"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cmi.2023.02.013","article-title":"Long-term treatment outcomes in patients with multidrug-resistant tuberculosis","volume":"29","author":"C Maier","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1093\/infdis\/jiaf057","article-title":"Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis","volume":"231","author":"J A Hughes","year":"2025","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"P809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"L Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5588\/ijtldopen.25.0152","article-title":"Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy","volume":"2","author":"L Kuksa","year":"2025","journal-title":"IJTLD Open"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1038\/s41467-024-53273-7","article-title":"Risk-stratified treatment for drug-susceptible pulmonary tuberculosis","volume":"15","author":"V K Chang","year":"2024","journal-title":"Nat Commun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.202101-0117OC","article-title":"Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials","volume":"204","author":"M Z Imperial","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/thorax-2023-220249","article-title":"Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis","volume":"79","author":"J R Campbell","year":"2024","journal-title":"Thorax"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2003492","DOI":"10.1183\/13993003.03492-2020","article-title":"Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model","volume":"58","author":"J Heyckendorf","year":"2021","journal-title":"Eur Respir J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2200765","DOI":"10.1183\/13993003.00765-2022","article-title":"Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany","volume":"60","author":"R Otto-Knapp","year":"2022","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"a018192","DOI":"10.1101\/cshperspect.a018192","article-title":"Transmission and Institutional Infection Control of Tuberculosis","volume":"6","author":"E A Nardell","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.5588\/ijtld.18.0173","article-title":"Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878\u20131940","volume":"22","author":"P R Donald","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref23","first-page":"983","article-title":"[Tuberculosis Infection Control & Hygiene \u2013 Recommendations of the DZK]","volume":"77","author":"P Witte","year":"2023","journal-title":"Pneumologie"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2731-0729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:14:50Z","timestamp":1772756090000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2731-0729"}},"subtitle":["Aktualisierte Empfehlungen auf Basis der WHO-Leitlinien 2025"],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":22,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2731-0729","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}